
Mission Bio
Total Raised
$114.26MInvestors Count
28Deal Terms
2Funding, Valuation & Revenue
11 Fundings
Mission Bio has raised $114.26M over 11 rounds.
Mission Bio's latest funding round was a Unattributed VC for on August 5, 2025.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
8/5/2025 | Unattributed VC | 2 | ||||
4/1/2022 | Angel - II | 1 | ||||
8/13/2020 | Series C | $70M | 7 | |||
7/11/2018 | Series B | |||||
12/8/2017 | Grant |
Date | 8/5/2025 | 4/1/2022 | 8/13/2020 | 7/11/2018 | 12/8/2017 |
|---|---|---|---|---|---|
Round | Unattributed VC | Angel - II | Series C | Series B | Grant |
Amount | $70M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 2 | 1 | 7 |
Mission Bio Deal Terms
2 Deal Terms
Mission Bio's deal structure is available for 2 funding rounds, including their Series B from July 11, 2018.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
Mission Bio Investors
28 Investors
Mission Bio has 28 investors. Ally Bridge Group invested in Mission Bio's Unattributed VC funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
8/5/2025 | 8/5/2025 | 2 Other Investors, Unattributed VC (2025) | Venture Capital | Hong Kong | ||
4/1/2022 | 4/1/2022 | 1 Angel - II | Angel Investor (Group) | California | ||
10/17/2017 | 8/13/2020 | 4 Series D, Series A (2017), Series B (2018), Series C (2020) | Venture Capital | California | ||
Venture Capital | California | |||||
Venture Capital | New Hampshire |
First funding | 8/5/2025 | 4/1/2022 | 10/17/2017 | ||
|---|---|---|---|---|---|
Last Funding | 8/5/2025 | 4/1/2022 | 8/13/2020 | ||
Investor | |||||
Rounds | 2 Other Investors, Unattributed VC (2025) | 1 Angel - II | 4 Series D, Series A (2017), Series B (2018), Series C (2020) | ||
Board Seats | |||||
Type | Venture Capital | Angel Investor (Group) | Venture Capital | Venture Capital | Venture Capital |
Location | Hong Kong | California | California | California | New Hampshire |
Compare Mission Bio to Competitors

NanoCellect Biomedical specializes in the development and manufacturing of microfluidic cell sorting technology for the biomedical research sector. The company offers a range of cell sorters and accessories designed to enhance precision and maintain high cell viability during sorting processes, suitable for applications in genomics, antibody discovery, and other scientific research areas. NanoCellect's products are utilized by researchers in fields such as stem cell research, plant biology, genomics, antibody discovery, cell line development, and gene editing. NanoCellect Biomedical was formerly known as NanoSort. It was founded in 2009 and is based in San Diego, California.
uFluidix specializes in the custom fabrication of microfluidic devices and chips, operating within the microtechnology industry. The company specializes in manufacturing silicone and thermoplastic components with high precision for various microfluidic applications. uFluidix primarily serves sectors that require advanced microfluidic solutions, such as point-of-care diagnostics, drug delivery, and cancer research. It was founded in 2010 and is based in Toronto, Canada.

Dolomite Microfluidics is involved in the design and manufacture of microfluidic products for applications in biotechnology, chemistry, food and cosmetics, and academic research sectors. The company provides modular systems, components, and solutions for drug encapsulation, droplet manufacture, and particle generation, as well as tools for biological analysis and precision manufacturing of emulsions and foams. Dolomite Microfluidics serves researchers and professionals in the life sciences, materials science, and chemical engineering fields. It was founded in 2005 and is based in Royston, England.
Achira Labs is a medical technology company specializing in point-of-care testing within the healthcare sector. The company offers a microfluidics-based platform that includes a fluorescence-based reader and integrated microfluidic cartridges, designed to deliver reliable lab-quality results from capillary blood samples. Achira Labs primarily serves the medical diagnostics industry. It was founded in 2009 and is based in Bangalore, India.
Parallel Fluidics specializes in microfluidic manufacturing and prototyping within the microfluidics domain. The company produces microfluidic devices using production-grade materials and technologies like transition molding and embedded hardware. Parallel Fluidics serves sectors that require microfluidic technology for research and development, including the biomedical and aerospace industries. It was founded in 2020 and is based in Boston, Massachusetts.
Okomera is a company that operates in the cancer care industry. It provides treatment intelligence derived from patient biopsies, utilizing tumor-on-chip technology and AI imaging to inform drug development and clinical decision-making. The company's platform is designed to facilitate testing of treatments, aiming to improve the predictability of preclinical studies and support applications from CRISPR to T-cell potency and drug screening. It was founded in 2020 and is based in Paris, France.
Loading...

